Last reviewed · How we verify
PSA-Activated PSA-PAH1
At a glance
| Generic name | PSA-Activated PSA-PAH1 |
|---|---|
| Also known as | PRX302, Topsalysin |
| Sponsor | Sophiris Bio Corp |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prostate Specific Antigen Levels of Individuals Living in Rural Areas
- PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |